RecruitingNot ApplicableNCT04030676

QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Enrollment

196 participants

Start Date

Jul 17, 2019

Study Type

INTERVENTIONAL

Conditions

Cytomegalovirus Infections

Summary

CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a blood test called QuantiFERON-CMV can predict which organ transplant recipients are most at risk of getting a cytomegalovirus (CMV) infection after receiving a bowel or liver transplant from a living donor. CMV is a common virus that can be dangerous for transplant patients with weakened immune systems. **You may be eligible if...** - You are receiving an organ from a related living donor (bowel or liver transplant) - Your doctor needs to assess your risk of CMV infection post-transplant **You may NOT be eligible if...** - You are receiving a deceased donor transplant - You do not meet the specific transplant criteria for the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.